LCP
ANIK icon

Lombardia Capital Partners’s Anika Therapeutics ANIK Stock Holding History

Lombardia Capital Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-231,393
Closed -$8.83M – 220
2015
Q4 		$8.83M Sell
231,393
-416,239
-64% -$15.9M 0.44% 87
2015
Q3 		$20.6M Sell
647,632
-204,189
-24% -$7.12M 0.99% 28
2015
Q2 		$28.1M Buy
851,821
+112,497
+15% +$4.01M 0.95% 33
2015
Q1 		$30.4M Buy
739,324
+598,662
+426% +$24.2M 0.91% 30
2014
Q4 		$5.73M Buy
+140,662
New +$5.5M 0.17% 152

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lombardia Capital Partners's ANIK Position: Q1 2016 in Review

Lombardia Capital Partners sold out of Anika Therapeutics (ANIK) in Q1 2016, closing a stake of 231,393 shares — an estimated $8.83M sold.

Lombardia Capital Partners first reported a position in ANIK in Q4 2014 and held it in 5 quarters. The position peaked at $30.4M in Q1 2015. 162 funds tracked by Wall St. Rank hold ANIK as of Q1 2016.

  • Lombardia Capital Partners reported no remaining Anika Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Lombardia Capital Partners sold 231,393 Anika Therapeutics shares in Q1 2016, an estimated $8.83M.
  • Lombardia Capital Partners first reported a position in Anika Therapeutics in Q4 2014 and held it in 5 quarters.
  • Lombardia Capital Partners's Anika Therapeutics position peaked at $30.4M in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2016.

Based on Lombardia Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.